Dr Georgina Wood
Telephone:
Location:
- University College Hospital
GMC/GDC number:
7090274
Professional background
Dr Georgina Wood is a consultant medical oncologist at University College London Hospital. She specialises in the systemic treatment of bone and soft tissue sarcomas, within the London Sarcoma Service, one of the largest sarcoma services in Europe. Dr Wood completed her medical oncology training at University College London.
Dr Wood has a strong interest in translational research and during her general internal medicine training undertook an MSc in Cancer Therapeutics at Bart's Cancer Institute. She completed her PhD investigating the role of aberrant signalling pathways in chemotherapy and PARP inhibitor resistance at Bart's Cancer Institute, University of London in 2020.
Dr Wood is actively involved in national and international clinical research projects, working to improve outcomes for sarcoma patients. In 2021 she was awarded an ECMC JING: TNG fellowship to develop an early phase clinical trial proposal for osteosarcoma patients and has continued this work within the FOSTER consortium. She is an investigator for multiple phase II/III clinical trials within the research portfolio at the London Sarcoma Service.
Dr Wood has an interest in global oncology and is a founding member of the UK Global Cancer Network, working to improve cancer outcomes in low- and middle-income countries (LMICs). She has worked across East Africa as international faculty with the RCP for the oncology Medical Training and Fellowship (METAF) programme. She is also on the steering committee for the ‘Cancer Control in LMICs’ conference held annually as part of London Global Cancer Week.
Dr Wood is a member of the British Sarcoma Group, FOSTER consortium, EORTC Soft Tissue and Bone Sarcoma group, NCRI sarcoma network, GeNotes Oncogenomics working group, UK GCN, ECMC JING alumni, CTOS, ESMO and ASCO.
Specialties
Research interests
Bone sarcomas
Soft tissue sarcomas
Gastrointestinal stromal tumours
Publications
Wood, GE., Graves, LA., Rubin, EM., Reed, DR., Riedel, RF., Strauss, SJ. Bad to the Bone: Emerging Approaches to Aggressive Bone Sarcomas. ASCO Educational Book. 2023 May;43:e390306.
Wood, GE., Chamberlain, F., Tran, B., Conduit, C., Liow, E., Nicol, D., Shamash, J., Alifrangis, C., Rajan, P. Treatment de-escalation for stage II seminoma. Nat Rev Urol. 2023 Mar 7.
Hoare JI, Hockings H, Saxena J, Silva VL, Haughey MJ, Wood GE, Nicolini F, Mirza H, McNeish IA, Huang W, Maniati E, Graham TA, Lockley M. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. Gynaecol Oncol. 2022 Oct;167 (1):96-106
Wood, GE., Hockings, H., Hilton, DM., Kermorgant, S. The role of MET in chemotherapy resistance. Oncogene. 2021 Mar;40 (11): 1927-1941.
Wood, GE., Ledermann, J. Adjuvant and post-surgical treatment in high grade epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2022 Jan;78:64-73..
Hockings, H., Wood, GE., McDermott, J., Narayanan, P., Hameeduddin, A., Miller, R. E., Lockley, M. Bevacizumab Enables Surgery in Previously Inoperable Patients with Advanced Low-Grade Serous Ovarian Cancer. European Journal of Surgery Case Reports. 2020 Volume 1(1): 2-5.
Wood, G., Grenader, T., Nash, S., Adams, R., Kaplan, R., Fisher, D., Maughan, T., Bridgewater, J. Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study. Anticancer Drugs. 2017 Jun;28(5):546-550.
Vinkovic, M., Dunn, G., Wood, GE., Hussain J., Wood, S and Gill, R. Cleavage of nicotinamide adenine dinucleotides by the ribosome inactivating protein of Momordica chariantia. Acta Crystallogr F Struct Biol Commun. 2015 Sep;71(Pt 9):1152-5.
Wood, GE., McNicholas, J. Coma Query Cause. BMJ Case Rep. 2015 May 6;2015:bcr2014205592.